Logo image of SYNH

SYNEOS HEALTH INC (SYNH) Stock Fundamental Analysis

NASDAQ:SYNH - Nasdaq - US87166B1026 - Common Stock - Currency: USD

42.98  +0.01 (+0.02%)

After market: 42.97 -0.01 (-0.02%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to SYNH. SYNH was compared to 55 industry peers in the Life Sciences Tools & Services industry. SYNH has a medium profitability rating, but doesn't score so well on its financial health evaluation. A decent growth rate in combination with a cheap valuation! Better keep an eye on SYNH.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

SYNH had positive earnings in the past year.
SYNH had a positive operating cash flow in the past year.
SYNH had positive earnings in each of the past 5 years.
In the past 5 years SYNH always reported a positive cash flow from operatings.
SYNH Yearly Net Income VS EBIT VS OCF VS FCFSYNH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M 300M 400M

1.2 Ratios

SYNH has a better Return On Assets (0.88%) than 70.31% of its industry peers.
SYNH has a better Return On Equity (2.04%) than 71.88% of its industry peers.
SYNH has a Return On Invested Capital of 4.23%. This is in the better half of the industry: SYNH outperforms 70.31% of its industry peers.
The Average Return On Invested Capital over the past 3 years for SYNH is significantly below the industry average of 13.27%.
Industry RankSector Rank
ROA 0.88%
ROE 2.04%
ROIC 4.23%
ROA(3y)2.83%
ROA(5y)2.12%
ROE(3y)6.82%
ROE(5y)5.13%
ROIC(3y)4.99%
ROIC(5y)4.67%
SYNH Yearly ROA, ROE, ROICSYNH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 10 20 30 40 50

1.3 Margins

SYNH has a better Profit Margin (1.31%) than 70.31% of its industry peers.
SYNH's Profit Margin has improved in the last couple of years.
SYNH's Operating Margin of 6.33% is fine compared to the rest of the industry. SYNH outperforms 65.63% of its industry peers.
In the last couple of years the Operating Margin of SYNH has grown nicely.
SYNH has a worse Gross Margin (22.14%) than 84.38% of its industry peers.
SYNH's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 6.33%
PM (TTM) 1.31%
GM 22.14%
OM growth 3Y5.34%
OM growth 5Y13.1%
PM growth 3Y20.73%
PM growth 5YN/A
GM growth 3Y1.57%
GM growth 5Y0.02%
SYNH Yearly Profit, Operating, Gross MarginsSYNH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 10 20

More info and screens

3

2. Health

2.1 Basic Checks

SYNH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for SYNH has been reduced compared to 1 year ago.
SYNH has a better debt/assets ratio than last year.
SYNH Yearly Shares OutstandingSYNH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M
SYNH Yearly Total Debt VS Total AssetsSYNH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2B 4B 6B 8B

2.2 Solvency

Based on the Altman-Z score of 1.46, we must say that SYNH is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 1.46, SYNH perfoms like the industry average, outperforming 43.75% of the companies in the same industry.
SYNH has a debt to FCF ratio of 16.71. This is a negative value and a sign of low solvency as SYNH would need 16.71 years to pay back of all of its debts.
The Debt to FCF ratio of SYNH (16.71) is better than 65.63% of its industry peers.
A Debt/Equity ratio of 0.77 indicates that SYNH is somewhat dependend on debt financing.
SYNH has a worse Debt to Equity ratio (0.77) than 79.69% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF 16.71
Altman-Z 1.46
ROIC/WACC0.39
WACC10.92%
SYNH Yearly LT Debt VS Equity VS FCFSYNH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 1B 2B 3B

2.3 Liquidity

SYNH has a Current Ratio of 1.20. This is a normal value and indicates that SYNH is financially healthy and should not expect problems in meeting its short term obligations.
SYNH has a worse Current ratio (1.20) than 93.75% of its industry peers.
SYNH has a Quick Ratio of 1.20. This is a normal value and indicates that SYNH is financially healthy and should not expect problems in meeting its short term obligations.
SYNH has a worse Quick ratio (1.20) than 82.81% of its industry peers.
Industry RankSector Rank
Current Ratio 1.2
Quick Ratio 1.2
SYNH Yearly Current Assets VS Current LiabilitesSYNH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 500M 1B 1.5B

More info and screens

4

3. Growth

3.1 Past

The earnings per share for SYNH have decreased strongly by -23.79% in the last year.
The Earnings Per Share has been growing by 13.74% on average over the past years. This is quite good.
The Revenue has been growing slightly by 0.01% in the past year.
The Revenue has been growing by 15.08% on average over the past years. This is quite good.
EPS 1Y (TTM)-23.79%
EPS 3Y13.48%
EPS 5Y13.74%
EPS Q2Q%-54.4%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y4.87%
Revenue growth 5Y15.08%
Sales Q2Q%0.39%

3.2 Future

Based on estimates for the next years, SYNH will show a small growth in Earnings Per Share. The EPS will grow by 3.17% on average per year.
Based on estimates for the next years, SYNH will show a small growth in Revenue. The Revenue will grow by 1.71% on average per year.
EPS Next Y-25.43%
EPS Next 2Y-6.79%
EPS Next 3Y-1.2%
EPS Next 5Y3.17%
Revenue Next Year-2.82%
Revenue Next 2Y-0.54%
Revenue Next 3Y1.03%
Revenue Next 5Y1.71%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SYNH Yearly Revenue VS EstimatesSYNH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1B 2B 3B 4B 5B
SYNH Yearly EPS VS EstimatesSYNH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3 4 5

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 11.37, which indicates a very decent valuation of SYNH.
Compared to the rest of the industry, the Price/Earnings ratio of SYNH indicates a rather cheap valuation: SYNH is cheaper than 100.00% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of SYNH to the average of the S&P500 Index (25.05), we can say SYNH is valued rather cheaply.
The Price/Forward Earnings ratio is 10.48, which indicates a very decent valuation of SYNH.
Based on the Price/Forward Earnings ratio, SYNH is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
SYNH is valuated cheaply when we compare the Price/Forward Earnings ratio to 21.07, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 11.37
Fwd PE 10.48
SYNH Price Earnings VS Forward Price EarningsSYNH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

95.31% of the companies in the same industry are more expensive than SYNH, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of SYNH indicates a rather cheap valuation: SYNH is cheaper than 85.94% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 27.53
EV/EBITDA 12.05
SYNH Per share dataSYNH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

The decent profitability rating of SYNH may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.83
EPS Next 2Y-6.79%
EPS Next 3Y-1.2%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SYNH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SYNEOS HEALTH INC

NASDAQ:SYNH (9/27/2023, 8:00:01 PM)

After market: 42.97 -0.01 (-0.02%)

42.98

+0.01 (+0.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-09 2023-08-09/bmo
Earnings (Next)11-02 2023-11-02/bmo
Inst Owners0%
Inst Owner Change0%
Ins Owners0.49%
Ins Owner Change0%
Market Cap4.46B
Analysts53.75
Price Target43.35 (0.86%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-9.02%
Min EPS beat(2)-29.57%
Max EPS beat(2)11.52%
EPS beat(4)2
Avg EPS beat(4)-6.43%
Min EPS beat(4)-29.57%
Max EPS beat(4)11.52%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.57%
Min Revenue beat(2)3.81%
Max Revenue beat(2)5.33%
Revenue beat(4)3
Avg Revenue beat(4)1.96%
Min Revenue beat(4)-4.69%
Max Revenue beat(4)5.33%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.13%
EPS NQ rev (1m)-1.52%
EPS NQ rev (3m)0.41%
EPS NY rev (1m)1.03%
EPS NY rev (3m)4.38%
Revenue NQ rev (1m)0.31%
Revenue NQ rev (3m)1.89%
Revenue NY rev (1m)0.55%
Revenue NY rev (3m)2.45%
Valuation
Industry RankSector Rank
PE 11.37
Fwd PE 10.48
P/S 0.82
P/FCF 27.53
P/OCF 17.62
P/B 1.28
P/tB N/A
EV/EBITDA 12.05
EPS(TTM)3.78
EY8.79%
EPS(NY)4.1
Fwd EY9.54%
FCF(TTM)1.56
FCFY3.63%
OCF(TTM)2.44
OCFY5.67%
SpS52.25
BVpS33.68
TBVpS-19.54
PEG (NY)N/A
PEG (5Y)0.83
Profitability
Industry RankSector Rank
ROA 0.88%
ROE 2.04%
ROCE 5.32%
ROIC 4.23%
ROICexc 4.29%
ROICexgc 32.26%
OM 6.33%
PM (TTM) 1.31%
GM 22.14%
FCFM 2.99%
ROA(3y)2.83%
ROA(5y)2.12%
ROE(3y)6.82%
ROE(5y)5.13%
ROIC(3y)4.99%
ROIC(5y)4.67%
ROICexc(3y)5.11%
ROICexc(5y)4.79%
ROICexgc(3y)50.55%
ROICexgc(5y)76.43%
ROCE(3y)6.27%
ROCE(5y)5.87%
ROICexcg growth 3Y-8.19%
ROICexcg growth 5Y1.51%
ROICexc growth 3Y6.95%
ROICexc growth 5Y27.79%
OM growth 3Y5.34%
OM growth 5Y13.1%
PM growth 3Y20.73%
PM growth 5YN/A
GM growth 3Y1.57%
GM growth 5Y0.02%
F-Score6
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF 16.71
Debt/EBITDA 4.56
Cap/Depr 37.2%
Cap/Sales 1.68%
Interest Coverage 250
Cash Conversion 43.05%
Profit Quality 227.34%
Current Ratio 1.2
Quick Ratio 1.2
Altman-Z 1.46
F-Score6
WACC10.92%
ROIC/WACC0.39
Cap/Depr(3y)28.14%
Cap/Depr(5y)26.15%
Cap/Sales(3y)1.32%
Cap/Sales(5y)1.31%
Profit Quality(3y)162.48%
Profit Quality(5y)341.03%
High Growth Momentum
Growth
EPS 1Y (TTM)-23.79%
EPS 3Y13.48%
EPS 5Y13.74%
EPS Q2Q%-54.4%
EPS Next Y-25.43%
EPS Next 2Y-6.79%
EPS Next 3Y-1.2%
EPS Next 5Y3.17%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y4.87%
Revenue growth 5Y15.08%
Sales Q2Q%0.39%
Revenue Next Year-2.82%
Revenue Next 2Y-0.54%
Revenue Next 3Y1.03%
Revenue Next 5Y1.71%
EBIT growth 1Y-27.25%
EBIT growth 3Y10.47%
EBIT growth 5Y30.16%
EBIT Next Year-2.87%
EBIT Next 3Y4.37%
EBIT Next 5Y3.5%
FCF growth 1Y-63.52%
FCF growth 3Y9.43%
FCF growth 5Y16.65%
OCF growth 1Y-47.97%
OCF growth 3Y10.26%
OCF growth 5Y16.58%